{"id":12429,"date":"2026-11-02T23:23:01","date_gmt":"2026-11-02T20:23:01","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?page_id=12429"},"modified":"2026-11-02T23:23:01","modified_gmt":"2026-11-02T20:23:01","slug":"vericiguat-uses-interactions-safety","status":"publish","type":"page","link":"https:\/\/www.ortaakarsu.net\/?page_id=12429","title":{"rendered":"Vericiguat: Uses, Interactions and Safety"},"content":{"rendered":"

Uses<\/h2>\n

Vericiguat stimulates soluble guanylate cyclase and is added to other treatment for selected adults with symptomatic chronic heart failure and reduced ejection fraction after a recent worsening event. It is intended for patients who have been stabilised after decompensation, rather than for self-treatment of sudden breathlessness or swelling.<\/p>\n

Administration<\/h2>\n

The tablet is taken by mouth with food. The heart-failure team adjusts treatment according to blood pressure and tolerability. Continue the other prescribed heart-failure medicines unless the clinician changes them. A missed dose or difficulty swallowing should be discussed using the instructions for the prescribed product.<\/p>\n

Safety<\/h2>\n

Low blood pressure and anaemia are important concerns. Report fainting, troublesome dizziness, unusual weakness or worsening heart-failure symptoms. Fluid status and blood pressure should be assessed before starting. People with very low blood pressure, dialysis or severe liver impairment need particular review because evidence is limited.<\/p>\n

Interactions<\/h2>\n

Riociguat or another soluble guanylate-cyclase stimulator is contraindicated. Combining vericiguat with a PDE5 inhibitor is not recommended because symptomatic hypotension may increase; the US avanafil label specifically contraindicates its use with vericiguat. Nitrates are not subject to the same blanket prohibition as with riociguat, but blood pressure and limited long-acting nitrate experience still require assessment. Sacubitril\/valsartan is an established compatible background treatment.<\/p>\n

Pregnancy and breastfeeding<\/h2>\n

It should not be used in pregnancy. US labelling explicitly lists pregnancy as a contraindication and requires effective contraception during treatment and for one month afterwards. Human milk data are lacking; breastfeeding and treatment decisions require discussion, and US labelling recommends not breastfeeding.<\/p>\n

Adverse effects<\/h2>\n

Hypotension and anaemia are the main adverse effects. Dizziness, headache, nausea and indigestion can occur. Do not change treatment solely because a new symptom resembles a listed adverse effect; the heart-failure team should assess it.<\/p>\n

Sources<\/h2>\n